Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

755.99 +19.53 (+2.65%)
Streaming Delayed Price Updated: 11:36 AM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 309,398
Open 739.27
Bid (Size) 755.22 (1)
Ask (Size) 756.05 (4)
Prev. Close 736.46
Today's Range 739.27 - 756.62
52wk Range 538.01 - 779.00
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
 
Via Benzinga

Performance

YTD
+4.93%
+4.93%
1 Month
+4.93%
+4.93%
3 Month
+0.97%
+0.97%
6 Month
+31.09%
+31.09%
1 Year
+24.22%
+24.22%

More News

Read More
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
Via Benzinga
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
Via Benzinga
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
Via The Motley Fool
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
Via Benzinga
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Via Investor's Business Daily
Check Out What Whales Are Doing With REGN
Via Benzinga
Check Out What Whales Are Doing With REGN
Via Benzinga
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
Via Investor's Business Daily
What This Drug News Could Mean for Sanofi Shareholders
Via The Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
Via InvestorPlace
Four Undervalued Healthcare Stocks for 2023
Via MarketBeat
Exposures COVID-19
CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker
Via Benzinga
3 Growth Stocks That Could Rocket Higher in 2023
Via The Motley Fool
Jim Cramer Says He's 'Still Feeling Good' About These 5 Stocks From 'Mutilated' Nasdaq
Via Benzinga
Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
2 Unstoppable Dividend Growth Stocks to Buy in 2023 and Beyond
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.